Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias

Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias

An open, randomized, multicentre study compared the efficacy and safety of the prototype azalide, azithromycin, and erythromycin in the treatment of atypical pneumonias. Azithromycin was administered for five days at a dosage of 250 mg bd on day 1 and 250 mg once daily on days 2 to 5. Erythromycin w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schoenwald, S, Gunjaca, M, Kolacny-Babic, L, Car, V, Govev, M
Format: Tagungsbericht
Sprache:eng
Schlagworte:
Chlamydia psittaci
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page no. A Sul.
container_issue
container_start_page no. A Sul.
container_title
container_volume 25
creator Schoenwald, S
Gunjaca, M
Kolacny-Babic, L
Car, V
Govev, M
description An open, randomized, multicentre study compared the efficacy and safety of the prototype azalide, azithromycin, and erythromycin in the treatment of atypical pneumonias. Azithromycin was administered for five days at a dosage of 250 mg bd on day 1 and 250 mg once daily on days 2 to 5. Erythromycin was given for ten days at 500 mg qid. Causative pathogens were identified by serological methods. Of 57 patients treated with azithromycin, Mycoplasma pneumoniae and Chlamydia psittaci were identified in 31 and eight patients, respectively. Of 44 patients treated with erythromycin, M. pneumoniae and C. psittaci were identified in 24 and eight patients, respectively. There were no therapeutic failures in either treatment group.
format Conference Proceeding
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_15621847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15621847</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_156218473</originalsourceid><addsrcrecordid>eNqNizsLwjAURjMoWB__IZNbITVN270o7rqXS72lkbzMTYf66xURXIUPDhzOt2CZkELldankiq2J7kKISlVNxi6ttwGiJu-4Hzg8dRqjt3OvHQd34xjnn3gvjchTREgWXfo80hx0D4YHh5P1TgNt2XIAQ7j7csP2p-O1Pech-seElDqrqUdjwKGfqCtUdSiaspZ_hy8S1kPi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>conference_proceeding</recordtype><pqid>15621847</pqid></control><display><type>conference_proceeding</type><title>Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias</title><source>Oxford University Press Journals Digital Archive Legacy</source><creator>Schoenwald, S ; Gunjaca, M ; Kolacny-Babic, L ; Car, V ; Govev, M</creator><contributor>Ridgway, GL (eds) ; Leigh, DA</contributor><creatorcontrib>Schoenwald, S ; Gunjaca, M ; Kolacny-Babic, L ; Car, V ; Govev, M ; Ridgway, GL (eds) ; Leigh, DA</creatorcontrib><description>An open, randomized, multicentre study compared the efficacy and safety of the prototype azalide, azithromycin, and erythromycin in the treatment of atypical pneumonias. Azithromycin was administered for five days at a dosage of 250 mg bd on day 1 and 250 mg once daily on days 2 to 5. Erythromycin was given for ten days at 500 mg qid. Causative pathogens were identified by serological methods. Of 57 patients treated with azithromycin, Mycoplasma pneumoniae and Chlamydia psittaci were identified in 31 and eight patients, respectively. Of 44 patients treated with erythromycin, M. pneumoniae and C. psittaci were identified in 24 and eight patients, respectively. There were no therapeutic failures in either treatment group.</description><identifier>ISSN: 0305-7453</identifier><language>eng</language><subject>Chlamydia psittaci</subject><ispartof>Journal of antimicrobial chemotherapy, 1990, Vol.25, p.no. A Sul.-no. A Sul.</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,776,780,785,786,23909,23910,25118</link.rule.ids></links><search><contributor>Ridgway, GL (eds)</contributor><contributor>Leigh, DA</contributor><creatorcontrib>Schoenwald, S</creatorcontrib><creatorcontrib>Gunjaca, M</creatorcontrib><creatorcontrib>Kolacny-Babic, L</creatorcontrib><creatorcontrib>Car, V</creatorcontrib><creatorcontrib>Govev, M</creatorcontrib><title>Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias</title><title>Journal of antimicrobial chemotherapy</title><description>An open, randomized, multicentre study compared the efficacy and safety of the prototype azalide, azithromycin, and erythromycin in the treatment of atypical pneumonias. Azithromycin was administered for five days at a dosage of 250 mg bd on day 1 and 250 mg once daily on days 2 to 5. Erythromycin was given for ten days at 500 mg qid. Causative pathogens were identified by serological methods. Of 57 patients treated with azithromycin, Mycoplasma pneumoniae and Chlamydia psittaci were identified in 31 and eight patients, respectively. Of 44 patients treated with erythromycin, M. pneumoniae and C. psittaci were identified in 24 and eight patients, respectively. There were no therapeutic failures in either treatment group.</description><subject>Chlamydia psittaci</subject><issn>0305-7453</issn><fulltext>true</fulltext><rsrctype>conference_proceeding</rsrctype><creationdate>1990</creationdate><recordtype>conference_proceeding</recordtype><recordid>eNqNizsLwjAURjMoWB__IZNbITVN270o7rqXS72lkbzMTYf66xURXIUPDhzOt2CZkELldankiq2J7kKISlVNxi6ttwGiJu-4Hzg8dRqjt3OvHQd34xjnn3gvjchTREgWXfo80hx0D4YHh5P1TgNt2XIAQ7j7csP2p-O1Pech-seElDqrqUdjwKGfqCtUdSiaspZ_hy8S1kPi</recordid><startdate>19900101</startdate><enddate>19900101</enddate><creator>Schoenwald, S</creator><creator>Gunjaca, M</creator><creator>Kolacny-Babic, L</creator><creator>Car, V</creator><creator>Govev, M</creator><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>19900101</creationdate><title>Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias</title><author>Schoenwald, S ; Gunjaca, M ; Kolacny-Babic, L ; Car, V ; Govev, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_156218473</frbrgroupid><rsrctype>conference_proceedings</rsrctype><prefilter>conference_proceedings</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Chlamydia psittaci</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schoenwald, S</creatorcontrib><creatorcontrib>Gunjaca, M</creatorcontrib><creatorcontrib>Kolacny-Babic, L</creatorcontrib><creatorcontrib>Car, V</creatorcontrib><creatorcontrib>Govev, M</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schoenwald, S</au><au>Gunjaca, M</au><au>Kolacny-Babic, L</au><au>Car, V</au><au>Govev, M</au><au>Ridgway, GL (eds)</au><au>Leigh, DA</au><format>book</format><genre>proceeding</genre><ristype>CONF</ristype><atitle>Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias</atitle><btitle>Journal of antimicrobial chemotherapy</btitle><date>1990-01-01</date><risdate>1990</risdate><volume>25</volume><spage>no. A Sul.</spage><epage>no. A Sul.</epage><pages>no. A Sul.-no. A Sul.</pages><issn>0305-7453</issn><abstract>An open, randomized, multicentre study compared the efficacy and safety of the prototype azalide, azithromycin, and erythromycin in the treatment of atypical pneumonias. Azithromycin was administered for five days at a dosage of 250 mg bd on day 1 and 250 mg once daily on days 2 to 5. Erythromycin was given for ten days at 500 mg qid. Causative pathogens were identified by serological methods. Of 57 patients treated with azithromycin, Mycoplasma pneumoniae and Chlamydia psittaci were identified in 31 and eight patients, respectively. Of 44 patients treated with erythromycin, M. pneumoniae and C. psittaci were identified in 24 and eight patients, respectively. There were no therapeutic failures in either treatment group.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1990, Vol.25, p.no. A Sul.-no. A Sul.
issn 0305-7453
language eng
recordid cdi_proquest_miscellaneous_15621847
source Oxford University Press Journals Digital Archive Legacy
subjects Chlamydia psittaci
title Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T13%3A34%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=proceeding&rft.atitle=Comparison%20of%20azithromycin%20and%20erythromycin%20in%20the%20treatment%20of%20atypical%20pneumonias&rft.btitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Schoenwald,%20S&rft.date=1990-01-01&rft.volume=25&rft.spage=no.%20A%20Sul.&rft.epage=no.%20A%20Sul.&rft.pages=no.%20A%20Sul.-no.%20A%20Sul.&rft.issn=0305-7453&rft_id=info:doi/&rft_dat=%3Cproquest%3E15621847%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15621847&rft_id=info:pmid/&rfr_iscdi=true